Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin and Pucotenlimab in Locally Advanced Anal Squamous Cell Carcinoma
NCT07800000Phase 2Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin, pucotenlimab in anal canal squamous cell carcinoma (SCCA). Planned start Sep 2026; status: not yet recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
anal canal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT07800000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07800000.